Document Detail


Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration.
MedLine Citation:
PMID:  23194475     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Chronic exposure to glucocorticoids might result not only in insulin resistance or cognitive deficits, but it is also considered as a risk factor for pathologies such as Alzheimer's disease. Propranolol is a β-adrenergic antagonist commonly used in the treatment of hypertension or acute anxiety. The effects of propranolol (5 mg/kg) have been tested in a model of chronic corticosterone administration (100 μg/ml, 4 wk) in drinking water. Corticosterone administration led to cognitive impairment in the novel object recognition test that was reversed by propranolol. Increased levels of Aβ in the hippocampus of corticosterone-treated mice were counteracted by propranolol treatment, purportedly through an increased IDE expression. Chronic corticosterone treatment induced responses characteristic of insulin resistance, as increased peripheral insulin levels, decreased activation of the insulin receptor (pIR) and decreased associated intracellular pathways (pAkt). These effects might be related to a decreased c-Jun N terminal kinase 1 expression. Again, propranolol was able to counteract all corticosterone-induced effects. One of the main kinases involved in tau phosphorylation, glycogen synthase kinase 3β (GSK3β), which is inactivated by phosphorylation by pAkt, was found to be decreased after corticosterone and increased after propranolol treatment. Concomitant changes in pTau expression were found. Overall, these data further strengthen the potential of propranolol as a therapeutic agent for pathologies associated with the interaction glucocorticoids-insulin resistance and the development of relevant cellular processes for Alzheimer's disease.
Authors:
Marta Dobarro; Lourdes Orejana; Norberto Aguirre; Maria J Ramírez
Related Documents :
21166955 - Ha1077, a rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the...
10601275 - Casein kinase i-dependent phosphorylation and stability of the yeast multidrug transpor...
6195015 - Polyglutamyl peptides: a new class of inhibitors of type-2 casein kinases.
21406225 - Mkk7γ1 reverses nerve growth factor signals: proliferation and cell death instead of n...
20708295 - Obesity abrogates the concentration-dependent effect of leptin on endogenous cholestero...
215195 - Subunit dissociation in the allosteric regulation of glycerol kinase from escherichia c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-30
Journal Detail:
Title:  The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)     Volume:  -     ISSN:  1469-5111     ISO Abbreviation:  Int. J. Neuropsychopharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815893     Medline TA:  Int J Neuropsychopharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-10     Citation Subset:  -    
Affiliation:
Dpto Farmacologia, Universidad de Navarra, Pamplona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impaired hormonal counterregulation to biochemical hypoglycaemia does not explain the high incidence...
Next Document:  Clerodane Diterpenoids from Croton crassifolius.